期刊文献+

雷帕霉素对膀胱癌T24细胞增殖及侵袭能力的影响 被引量:6

Rapamycin Inhibits Proliferation and Invasion of Human Bladder Carcinoma Cell Line T24 in vitro
暂未订购
导出
摘要 目的探讨雷帕霉素对膀胱癌T24细胞增殖和侵袭能力的影响。方法将T24细胞贴壁培养于10%胎牛血清、100U/mL青霉素、100μg/mL链霉素的RPMI1640培养液中,37℃、5%CO2饱和湿度培养箱中培养。取对数生长期细胞,随机分为处理组(加入浓度为10~1000nmol/L的雷帕霉素)和对照组(不加药物),每天更换RPMI1640培养液。采用MTT法检测各组细胞生长抑制率,transwell小室法检测细胞体外侵袭能力的变化。结果雷帕霉素对T24细胞有增殖抑制作用,呈剂量依赖关系。transwell法检测结果显示,雷帕霉素处理后的T24細胞体外侵袭能力明显下降,与雷帕霉素呈剂量依赖性。结论雷帕霉素具有抑制膀胱癌T24细胞增殖和侵袭能力的作用。 Objective To investigate the effects of rapamycin on proliferation and invasion of human bladder cancer cell T24.Methods T24 cells were maintained in RPMI-1640 containing 10% fetal bovine serum,penicillin(100 U/mL)and streptomycin(100 μg/mL).Cells were cultured at 37 ℃ in a 5% CO2 incubator.T24 cells in logarithmic growth phase were selected and randomly divided into experimental group[treated with various concentrations of rapamycin solution(10 to 1 000 nmol/L)]and control group(treated with RPMI 1640).Growth inhibition rates of the tumor cells were measured by MTT colorimetry.The changes of invasiveness of cells were measured by transwell chamber assay.Results Rapamycin inhibited proliferation of T24 tumor cells in a concentration-dependent manner and inhibited invasiveness of T24 cells in transwell chamber assay.Conclusion Rapamycin inhibited growth and invasiveness of bladder carcinoma cells.
出处 《中国医科大学学报》 CAS CSCD 北大核心 2011年第4期301-303,共3页 Journal of China Medical University
基金 辽宁省科技计划项目(2009225008-14)
关键词 雷帕霉素 T24细胞 增殖 侵袭 rapamycin T24 cell proliferation invasion
  • 相关文献

参考文献10

  • 1Turner AP, Shaffer VO, Araki K, et al. Sirolimus enhances the mag- nitude and quality of viral-specific CD8 (+) T-cell responses to vae- einia vires vaccination in rhesus macaques [J]. Am J Transplant, 2011,11(3) :613-618.
  • 2Shirouzu Y,Ryschich E,Salnikova O,et al.Rapamycin inhibits pro- liferation and migration of hepatoma cells in vitro ~J~. J Surg Res, 2010,159(2) :705-713.
  • 3Garrido-Laguna I,Tan AC, Uson M,et al.Integrated preclinical and clinical development of mTOR inhibitors in pancreatic cancer[J]. Br J Cancer,2010, 103(5) :649-655.
  • 4Parada B, Reis F, Figueiredo A,et al. Inhibition of bladder tumour growth by sirolimus in an experimental eareinogenesis modelIJ~. BJU Int,2011,107( 1 ) : 135-143.
  • 5Hansel DE,Platt E,Orloff M,et al.Mammalian target of rapamyein (mTOR) regulates eellular proliferation and tumor growth in urothe- lial carcinoma[ J 1. Am J Pathol, 2010,176( 6 ) : 3062-3072.
  • 6Zhang JF, Liu JJ, Lu MQ, et al.Rapamycin inhibits cell growth by in- duction of apoptosis on hepatoceHular carcinoma cells in vitro [J~. Transpl hnunol, 2007,17(3 ) : 162-168.
  • 7Schlosshauer PW, Li W, Lin KT, et al.Rapamycin by itself and addi- tively in combination with carboplatin inhibits the growth of ovarian cancer cells [ J 1- Gynecol Oncol, 2009, 114( 3 ) : 516-522.
  • 8Fechner G,Classen K,Schmidt D,et al. Rapamycin inhibits in vitro growth and release of angiogenetic factors in human bladder cancer [ J 1. Urology, 2009,73 ( 3 ) : 665-668.
  • 9Dancey JE.Clinical development of mammalian target of rapamycin inhibitors [ J l-Hematol Oncol Clin North Am, 2002, 16 (5) : 1101 - 1114.
  • 10Sehgal SN.Sirolimus : its discovery, biological properties, and mech- anism of action [ J ].Transplant Proc, 2003,35 (3 Supp 1 ) : 7S- 14S.

同被引文献74

  • 1彭晓琼,王志刚,冉海涛,杨春江,景香香,张群霞.低频超声辐射微泡造影剂对人乳腺癌细胞的生物学效应研究[J].中国超声医学杂志,2005,21(11):807-809. 被引量:18
  • 2张尔贤,俞丽君,周意琳,肖湘.Fe^(2+)诱发脂蛋白PUFA过氧化体系及对若干天然产物抗氧化作用的评价[J].生物化学与生物物理学报,1996,28(2):218-222. 被引量:129
  • 3Thoreen CC, Kang SA, Chang JW, et al. An ATP-competitive mam- malian target of rapamycin inhibitor reveals rapamycin-resistant func- tions of mTORC1. J Blot Chem, 2009, 284(12) : 8023-8032.
  • 4Kollmannsberger C, Hirte H, Siu LL, et al. Temsirolimus in combi- nation with carboplatin and paclitaxel in patients with advanced solid tumors: a NCIC-CTG, phase I , open-label dose-escalation study (IND 179). Ann Oncol, 2012, 23(1) : 238-244.
  • 5Naing A, Kurzrock R, Burger A, et al. Phase I trial of cixutumumab combined with temsirolimus in patients with advanced cancer. Clin Cancer Rcs, 2011, 17(18) : 6052-6060.
  • 6Griinwald V, Seidel C, Fenner M, et al. Treatment of everolimus- resistant metastatic renal cell carcinoma with VEGF-targeted thera- pies. Br J Cancer, 2011, 105 ( 11 ) : 1635-1639.
  • 7Guba M, yon Breitenbuch P, Steinbauer M, et al. Rapamycin inhib- its primary and metastatic tumor growth by antiangiogenesis: involve- ment of vascular endothelial growth factor. Nat Med, 2002, 8 ( 2 ) :128-135.
  • 8I Zeng Z, Sarbassov DD, Samudio IJ, et al. Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML. Blood, 2007, 109(8) : 3509-3512.
  • 9] Thoreen CC, Sabatini DM. Rapamycin inhibits mTORC1, but not completely. Autophagy, 2009, 5 (5) : 725-726.
  • 10Chang SB, Miron P, Miron A, et al. Rapamycin inhibits proliferation of estrogen-receptor-positive breast cancer cells. J Surg Res, 2007, 138(1): 37-44.

引证文献6

二级引证文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部